What Happened
- India's exports of Active Pharmaceutical Ingredients (APIs) reached Rs 41,500 crore in FY2024-25, surpassing total API imports of Rs 39,215 crore — a historic first.
- Despite the export milestone, China's share of India's API imports has risen to 74% (Rs 29,064 crore in FY25), up from 70% in FY2022-23, indicating continued concentrated dependence on a single country.
- The Production Linked Incentive (PLI) Scheme for bulk drugs, launched in March 2020, is credited with building domestic manufacturing capacity, with 28 of 41 targeted critical products now having greenfield production facilities.
- The government has framed this as a strategic shift toward an Atmanirbhar Bharat in pharmaceuticals, aiming to reduce vulnerability to supply disruptions from China.
- India's total pharmaceutical exports stood at USD 30.47 billion in FY25, registering 9.4% growth over the previous year.
Static Topic Bridges
PLI Scheme for Bulk Drugs — Policy Architecture
The Production Linked Incentive (PLI) Scheme for Key Starting Materials (KSMs), Drug Intermediates, and Active Pharmaceutical Ingredients was launched on 20 March 2020 under the Department of Pharmaceuticals. It has a total financial outlay of Rs 6,940 crore for the period FY2020-21 to FY2029-30. The scheme covers 41 identified critical products spread across four target segments — two fermentation-based (requiring at least 90% domestic value addition) and two chemical synthesis-based (requiring at least 70% domestic value addition).
- Launch date: 20 March 2020; Nodal ministry: Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals)
- Total outlay: Rs 6,940 crore over 10 years (FY2020-21 to FY2029-30)
- Products covered: 41 critical APIs/KSMs/Drug Intermediates with high import dependence
- 47 approved projects with committed investment of Rs 5,366 crore; domestic manufacturing capacity of ~56,800 tonnes per annum established
- Cumulative import savings: Rs 1,362 crore by March 2025; employment generated: 4,896 persons till December 2025
- Incentive structure: Sales-linked incentive paid for 6 years after commercial production starts
Connection to this news: The PLI scheme directly addresses the supply chain vulnerability that the API export milestone represents. The fact that exports now exceed imports is partly a function of the greenfield capacity built under PLI — though import dependence on China for inputs to that domestic manufacturing capacity remains a residual risk.
India's Position in Global Pharmaceuticals — "Pharmacy of the World"
India is the world's third-largest pharmaceutical producer by volume and the largest supplier of generic medicines globally, accounting for approximately 20% of global generic drug supply by volume. India also supplies approximately 60% of global vaccine demand. The country has over 3,000 pharmaceutical companies, 10,500 manufacturing units, and produces 60,000+ generic brands across 60 therapeutic areas.
- India supplies generics to over 200 countries; US is the top export destination (~34% share)
- India accounts for ~55% of Africa's total demand for generic medicines
- The US FDA has approved more Indian pharmaceutical manufacturing plants outside the US than from any other country
- API (bulk drug) exports comprise about 16% of India's total pharma exports by value; formulations and biologics form the remaining ~79%
- India's pharma sector market size: approximately USD 50 billion domestic + exports combined
Connection to this news: The shift from API import dependence to export surplus aligns with India's ambition to move up the pharmaceutical value chain — from being a generic formulations exporter to becoming a vertically integrated manufacturer that is self-sufficient even at the upstream API stage.
What Are Active Pharmaceutical Ingredients (APIs)?
An Active Pharmaceutical Ingredient (API) is the biologically active component in a drug product that produces the intended therapeutic effect. APIs are distinct from excipients (inactive ingredients like fillers and binders). Historically, India relied heavily on China for API imports because China's scale, subsidies, and lower environmental compliance costs made its APIs cheaper. This dependence created strategic vulnerabilities, sharply exposed during the COVID-19 pandemic supply disruptions of 2020.
- APIs are governed under the Drugs and Cosmetics Act, 1940 and Rules 1945 in India; Schedule M specifies Good Manufacturing Practices (GMP) for drug manufacturers
- Key therapeutic API categories: antibiotics (penicillin, amoxicillin), anti-diabetics (metformin), cardiovascular (atorvastatin), antipyretics (paracetamol)
- India's API import dependence on China peaked around 2020 (estimated 60-70% of critical APIs from China)
- The Drugs and Cosmetics (Amendment) Act and Quality Control Orders have been used to enforce domestic API standards
Connection to this news: The API self-reliance goal is not merely economic — it is a national security concern. The milestone of exports exceeding imports signals that India's domestic API manufacturing base is maturing, though Chinese dominance in the import basket (74%) means strategic vulnerability persists.
Key Facts & Data
- India API exports FY25: Rs 41,500 crore; API imports FY25: Rs 39,215 crore
- China's share of India's API imports: 74% in FY25 (up from 70% in FY2022-23)
- China API imports: Rs 25,551 cr (FY23) → Rs 27,055 cr (FY24) → Rs 29,064 cr (FY25)
- PLI Bulk Drugs outlay: Rs 6,940 crore; products covered: 41; tenure: FY2021-FY2030
- PLI manufacturing capacity created: ~56,800 tonnes/year across 28 products
- India total pharma exports FY25: USD 30.47 billion (9.4% YoY growth)
- India's global generic drug market share by volume: ~20%
- Indian API market projected size: USD 14.77 billion (2025) → USD 22.02 billion (2030)
- PLI import savings by March 2025: Rs 1,362 crore; direct employment: 4,896 persons